ID   LN-405
AC   CVCL_1378
SY   LN 405; LN405
DR   CLO; CLO_0007364
DR   CLDB; cl3242
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473369
DR   CCLE; LN405_CENTRAL_NERVOUS_SYSTEM
DR   Cell_Model_Passport; SIDM00343
DR   ChEMBL-Cells; CHEMBL3308756
DR   ChEMBL-Targets; CHEMBL1075491
DR   Cosmic; 687578
DR   Cosmic; 849868
DR   Cosmic; 910694
DR   Cosmic; 1746949
DR   Cosmic; 2302332
DR   Cosmic; 2367536
DR   Cosmic; 2580914
DR   Cosmic-CLP; 910694
DR   DepMap; ACH-002268
DR   DSMZ; ACC-189
DR   GDSC; 910694
DR   GEO; GSM326241
DR   GEO; GSM1670050
DR   IARC_TP53; 21474
DR   LINCS_LDP; LCL-1395
DR   PharmacoDB; LN405_845_2019
DR   Progenetix; CVCL_1378
DR   Wikidata; Q54902781
RX   PubMed=10416987;
RX   PubMed=20164919;
RX   PubMed=21406405;
RX   PubMed=22570425;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: ~60 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu62Arg (c.185T>G); Zygosity=Heterozygous (CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (PubMed=10416987; CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.81%; Native American=0%; East Asian, North=1.39%; East Asian, South=0%; South Asian=3.12%; European, North=55.54%; European, South=38.13% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=11416159; PubMed=22570425
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8
ST   D16S539: 10
ST   D18S51: 12,15
ST   D21S11: 29,31.2
ST   D3S1358: 14
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   D8S1179: 13
ST   FGA: 22,24
ST   Penta D: 8,11
ST   Penta E: 17
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 30
//
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21406405; DOI=10.1158/0008-5472.CAN-10-3112;
RA   Grzmil M., Morin P. Jr., Lino M.M., Merlo A., Frank S., Wang Y.,
RA   Moncayo G., Hemmings B.A.;
RT   "MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta
RT   signaling pathway in human glioblastoma.";
RL   Cancer Res. 71:2392-2402(2011).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//